Monday - January 26, 2026
GentiBio Receives Grant from Breakthrough T1D and the Helmsley Charitable Trust to Support POLARIS Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes
January 26, 2026
NEW YORK, Jan. 26 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:

* * *

GentiBio Receives Grant from Breakthrough T1D and the Helmsley Charitable Trust to Support POLARIS Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes

*

BOSTON, Jan. 26, 2026-GentiBio, Inc., a biotechnology company pioneering engineered regulatory T cell (EngTreg) therapies, today announc . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products